What Probiotics Demonstrably Do
Strip away the marketing and the probiotic evidence base is a short, specific, and genuinely useful list — dominated by diarrhea prevention around antibiotic use. Beyond that list, claims thin out fast. This page states each demonstrated effect with its real size, and then spends honest time on the claims that don't clear the bar.
What the evidence supports
- Specific strains measurably reduce antibiotic-associated diarrhea (roughly 40% relative reduction in pooled trials) and C. difficile-associated diarrhea (risk more than halved).
- Certain strains shorten acute infectious diarrhea in children by about a day — always alongside oral rehydration, which is the primary treatment.
- A defined multi-strain blend maintains remission in pouchitis, a narrow but well-replicated indication.
What remains uncertain
- IBS trials are real but modest and inconsistent — some strains help some people, and prediction remains poor.
- Claims about immunity, weight, skin, and mood in generally healthy people rest on thin or mixed evidence.
- Whether probiotics taken after an antibiotic course help or delay microbiome recovery remains a genuine, unresolved controversy.
Evidence last reviewed: August 15, 2026. Conclusions may change as new research is published.
what survives the trials
The Demonstrated List, Stated Sizes and All
Here is the full list of indications with replicated, meta-analyzed support — deliberately short. The order reflects evidence weight, not market size.
The Workhorse Indication: Around Antibiotics
Antibiotics damage the gut ecosystem as collateral damage — killing the commensals that normally crowd out pathogens, which is exactly when Clostridium difficile and other troublemakers move in. Probiotics are best documented as a hedge against that window. The landmark meta-analysis pooled randomized trials and found probiotics cut the rate of antibiotic-associated diarrhea by roughly 40% relative to placebo — about one case prevented for every 13 courses treated (Hempel et al., JAMA, 2012). The Cochrane review focused on the more serious outcome, C. difficile-associated diarrhea, and found the risk more than halved with probiotics given alongside antibiotics (Goldenberg et al., Cochrane, 2017). The strains with the deepest records here are Lactobacillus rhamnosus GG and Saccharomyces boulardii. Note the framing: the effect is prevention during the course, started close to the first antibiotic dose. That timing distinction matters, because of a controversy that deserves its own section.
The Post-Antibiotic Controversy
Taking probiotics after the antibiotics stop is a different question with a genuinely unsettled answer. A widely cited study gave volunteers a week-long antibiotic course, then either a probiotic blend, an autologous fecal transplant, or nothing, and tracked microbiome recovery. The striking finding: the probiotic group's microbiome recovered slower than the no-treatment group — the incoming strains appeared to occupy the niche the residents were trying to reclaim — while the fecal-transplant group snapped back in days (Suez et al., Cell, 2018). The trial is small and not the last word, but it landed hard for a reason: it flipped the reflexive advice. The defensible current position, which the parent topic adopts: probiotics have their clearest role during antibiotic courses for diarrhea prevention; for rebuilding afterward, the better-documented lever is fiber feeding the residents — and the fiber topic owns that dose math. Any persistent post-antibiotic diarrhea is clinician territory regardless.
IBS: Real but Modest
Irritable bowel syndrome is the largest commercial target for probiotics, and the evidence is — honestly — middling. The reference meta-analysis pooled 43 randomized trials of probiotics, prebiotics, and synbiotics in IBS and chronic constipation and found a real but modest effect: roughly a fifth fewer people with persistent symptoms, with wide variation between trials and strains (Ford et al., American Journal of Gastroenterology, 2014). Some strains — Lactobacillus plantarum 299v, Bifidobacterium longum 35624 — carry the most consistent individual records, and even those help some people and not others. The practical read: a defined-strain trial is reasonable for IBS, but the expectation should be "might help, verify for yourself over 4–8 weeks," not "treats IBS." The decision checklist walks through the logic.
⚠️ The pediatric and hospital lines
Two demonstrated uses are not do-it-yourself territory. In children, certain strains shorten acute infectious diarrhea by about a day — but oral rehydration is the primary treatment, and dehydration in a child is a medical matter, not a supplement matter (Allen et al., Cochrane, 2010). In neonatal intensive care, specific probiotic regimens reduce necrotizing enterocolitis in preterm infants in meta-analyses — a finding that belongs to hospital formularies and clinicians, not to a retail bottle. And in anyone with immune compromise, a central line, or critical illness, probiotics carry real risks of bloodstream infection; the FDA has repeatedly flagged such cases. These are boundaries, not trivia.
The Thin File
Everything else sits below the demonstrated line. The honest status of the common claims:
- 🧠 Mood and anxiety: the "psychobiotic" trials are small, promising, and nowhere near clinical standard — the gut-brain axis topic owns the full accounting.
- 🛡️ Immune defense in healthy people: some trials show fewer colds, but effects are small and inconsistent; the healthy-adult "daily shield" claim has no solid backing (Genome Medicine, 2016).
- ⚖️ Weight and metabolism: a few strains moved the needle slightly in small trials; the pooled picture does not support a weight-loss product.
- 🧴 Eczema and allergy prevention: genuinely mixed — some pregnancy-and-infant protocols show modest eczema reduction, others nothing; no basis for a general recommendation.
- ✈️ Traveler's diarrhea: modest pooled protection (roughly 15% fewer cases in older meta-analyses), most relevant for short, high-risk trips — and the checklist covers when that trade is worth it.
The Indication Map
Condensed for reference: what to pair with what, and the verdict.
| Indication | Best-documented strains | Typical effect size | Verdict |
|---|---|---|---|
| 💊 Antibiotic-associated diarrhea | L. rhamnosus GG; S. boulardii CNCM I-745; several blends | ~40% relative reduction; NNT ~13 | Demonstrated |
| 🧫 C. difficile-associated diarrhea | S. boulardii; L. rhamnosus GG; blends | Risk more than halved in pooled trials | Demonstrated |
| 🩺 Pouchitis remission | VSL#3 defined blend | Large in small trials | Demonstrated |
| 👶 Acute diarrhea in children | L. rhamnosus GG; S. boulardii | ~1 day shorter, alongside rehydration | Moderate |
| 🌊 IBS symptoms | L. plantarum 299v; B. longum 35624 | Modest, strain-specific, variable | Modest |
| ✈️ Traveler's diarrhea | S. boulardii; L. rhamnosus GG | Modest pooled protection | Modest |
| 🧴 Eczema prevention | Various, protocols vary | Inconsistent across trials | Weak |
| 🌤️ General wellness, healthy adults | Any retail product | No consistent benefit | Weak |
Practical Rules
- 💊 Pair the strain to the indication, not the mood. An antibiotic course calls for LGG or S. boulardii at trial dose; nothing on the demonstrated list is served by a random blend.
- ⏱️ Start early and stop when the job ends. The antibiotic-associated diarrhea evidence comes from starting near the first dose and continuing through the course — not from starting a week in or continuing forever after.
- 📓 Judge your own trial honestly. For the "might help" category, pick one defined strain, run 4–8 weeks, and compare your own symptom record before and after — a diary beats a feeling.
- 🩺 Route the serious symptoms to a clinician. Blood in stool, fever with diarrhea, dehydration, or symptoms persisting past the antibiotic course are medical matters — a probiotic belongs alongside that conversation, never instead of it.
Questions, Answered Briefly
- 💊 Will probiotics help my IBS? Possibly, modestly. The honest protocol is a defined strain with IBS trial support, a 4–8 week trial, and a decision based on your own symptom record — the checklist page has the full logic.
- 🛡️ Should I take one daily as insurance? The evidence for healthy adults is the weakest row on the table — the parent scorecard rates this Weak. Fiber and fermented foods are the better-documented default.
- ⏱️ During or after antibiotics? The demonstrated window is during, started near the first dose. The after-course question is contested — some evidence suggests post-antibiotic probiotics may slow recovery — so fiber-based rebuilding is the safer default afterward.
- 🔬 What about synbiotics — do they do more? The evidence mostly mirrors the probiotic-only results; the newer-terms page assesses that honestly.
The Bottom Line
- The demonstrated list is short and diarrhea-shaped — antibiotic-associated diarrhea, C. difficile prevention, pouchitis, and acute gastroenteritis in children carry the real evidence.
- Sizes stated: roughly 40% relative reduction in antibiotic-associated diarrhea (NNT ~13), C. difficile risk more than halved, about a day shorter diarrhea in kids.
- IBS is a "might help" category — modest, strain-specific effects worth a defined 4–8 week trial, not a promise.
- Everything else is thin — immunity, weight, skin, and mood claims in healthy people lack the trial base the marketing implies.
Related Topics
- Hempel et al., "Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis," JAMA (2012)
- Goldenberg et al., "Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children," Cochrane Database of Systematic Reviews (2017)
- Allen et al., "Probiotics for treating acute infectious diarrhoea," Cochrane Database of Systematic Reviews (2010)
- Ford et al., "Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis," The American Journal of Gastroenterology (2014)
- Suez et al., "Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT," Cell (2018)
- Kristensen et al., "Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials," Genome Medicine (2016)
- Mimura et al., "Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis," Gut (2004)
- McFarland, "Meta-analysis of probiotics for the prevention of traveler's diarrhea," Travel Medicine and Infectious Disease (2007)